查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595262

胜胜肽抗生素市场：按类型、疾病、给药途径、分销管道分类 - 全球预测 2025-2030

Peptide Antibiotics Market by Type, Disease, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

胜胜肽抗生素市场2023年估值为51.1亿美元，预计2024年将达到55.8亿美元，复合年增长率为9.74%，预计2030年将达到98亿美元。

胜肽抗生素是抗菌领域中的利基但快速增长的领域，包括具有抗菌特性的天然衍生或合成工程的胜肽基化合物。它们的范围主要取决于它们对抗多重抗药性（MDR）病原体的能力，这使它们成为应对日益严重的全球抗生素抗药性危机的重要工具。对胜肽抗生素的需求源于其独特的作用机制，该机制针对细菌膜并降低抗药性。特别是可望应用于农业治疗院内感染等严重感染疾病，以及防治动植物病害。胜胜肽抗生素的最终用途范围涵盖药品、农业生物技术和个人保健产品。

主要市场统计
基准年[2023] 51.1亿美元
预测年份 [2024] 55.8亿美元
预测年份 [2030] 98亿美元
复合年增长率（%） 9.74%

胜肽抗生素市场的驱动因素包括对新型抗菌药物的迫切需求、MDR细菌数量的增加以及胜肽技术研发投资的增加。一个主要的发展机会在于开发具有增强的稳定性和活性频谱的下一代胜胜肽抗生素。然而，市场面临生产成本高、潜在毒性以及与核准新抗菌药物相关的监管障碍等限制。此外，胜肽在体内的半衰期短也构成了需要创新解决方案的重大挑战。

为了抓住市场机会，公司应专注于提高稳定性和降低毒性的胜胜肽合成技术的进步，并与生物技术公司和研究机构建立策略联盟。促进重组DNA技术等胜胜肽工程平台的研究和探索混合胜肽也可以突破当前的限制。此外，透过专注于个人化医疗，我们可以利用胜肽抗生素的特异性来提供量身定制的治疗方案。该市场的特点是快速的科学进步和竞争格局，呈现出充满活力但充满挑战的格局。投资尖端研究、简化监管途径并积极开展研究合作的公司可能会在这个充满前景的市场中站稳脚跟。

市场动态：揭示快速发展的胜胜肽抗生素市场的关键市场洞察

供需的动态交互作用正在改变胜胜肽抗生素市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 细菌性皮肤感染疾病、血液感染疾病和医院感染等疾病的盛行率增加
    • 医院和诊所对胜胜肽抗生素的需求不断增长
    • 改善医疗基础设施
  • 市场限制因素
    • 严格的报销政策
  • 市场机会
    • 增加产品核可、产品发布和倡议
    • 在皮肤/骨骼再生、预防植入相关感染疾病、癌症治疗和基因转移方面的新用途
  • 市场挑战
    • 对胜肽抗生素不稳定性和毒性的担忧

波特五力：驾驭胜胜肽抗生素市场的策略工具

波特的五力框架是了解胜胜肽抗生素市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解胜胜肽抗生素市场的外部影响

外部宏观环境因素在塑造胜胜肽抗生素市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解胜胜肽抗生素市场竞争状况

对胜肽抗生素市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位基质胜胜肽抗生素市场供应商绩效评估

FPNV定位矩阵是评估胜胜肽抗生素市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了胜胜肽抗生素市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对胜肽抗生素市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 细菌性皮肤感染疾病、血液感染疾病和医院感染等疾病的盛行率增加
      • 医院和诊所对胜肽抗生素的需求增加
      • 改善医疗基础设施
    • 抑制因素
      • 严格的退费政策
    • 机会
      • 增加产品核可、产品发布和研发活动
      • 在皮肤和骨骼再生、预防植入相关感染疾病、癌症治疗和基因传递方面的新应用
    • 任务
      • 对胜肽抗生素不稳定性和毒性的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章胜胜肽抗生素市场：依类型

  • 非核醣体合成胜胜肽抗生素
  • 核醣体合成的胜肽抗生素

第七章胜胜肽抗生素市场：依疾病分类

  • 血流感染疾病
  • HABP/VABP
  • 皮肤感染疾病

第八章胜胜肽抗生素市场：依给药途径

  • 可注射的
  • 口服
  • 话题

第九章胜胜肽抗生素市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十章美洲胜肽抗生素市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太胜肽抗生素市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲胜肽抗生素市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly & Company
  • Eugia US LLC
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Holdings A/S
  • Pfizer Inc.
  • Sanofi SA
  • Savara Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma
Product Code: MRR-205091A88A0F

The Peptide Antibiotics Market was valued at USD 5.11 billion in 2023, expected to reach USD 5.58 billion in 2024, and is projected to grow at a CAGR of 9.74%, to USD 9.80 billion by 2030.

Peptide antibiotics, a niche yet burgeoning segment within the antimicrobial field, encompass naturally derived or synthetically engineered peptide-based compounds with antibacterial properties. Their scope is primarily defined by their ability to combat multi-drug resistant (MDR) pathogens, serving as a crucial tool in the growing global antibiotic resistance crisis. The necessity of peptide antibiotics arises from their unique mechanisms of action, targeting bacterial membranes and resulting in lower rates of resistance. They find applications across clinical settings for treating severe infections, particularly in hospital-acquired infections, and show promise in agriculture to prevent and treat plant and animal diseases. The end-use scope of peptide antibiotics spans pharmaceuticals, agricultural biotechnology, and personal care products.

KEY MARKET STATISTICS
Base Year [2023] USD 5.11 billion
Estimated Year [2024] USD 5.58 billion
Forecast Year [2030] USD 9.80 billion
CAGR (%) 9.74%

The market for peptide antibiotics is driven by the urgent need for novel antimicrobial agents, increased prevalence of MDR bacteria, and rising investment in research and development of peptide technologies. Key opportunities lie in the development of next-generation peptide antibiotics with enhanced stability and spectrum of activity. However, the market faces limitations such as high production costs, potential toxicity, and regulatory hurdles associated with the approval of new antimicrobial agents. Additionally, the short half-life of peptides in vivo poses a significant challenge that requires innovative solutions.

To capitalize on market opportunities, firms should focus on advancing peptide synthesis technologies to enhance stability and reduce toxicity, and fostering strategic collaborations with biotechnology companies and research institutions. Promoting research in peptide-engineering platforms like recombinant DNA technology and exploring hybrid peptides can also push the boundaries of current limitations. Further, a focus on personalized medicine could leverage the specificity of peptide antibiotics, offering tailored therapeutic options. The market is characterized by rapid scientific advancements and competitive pressures, indicating a vibrant yet challenging landscape. Companies that invest in cutting-edge research, streamline regulatory pathways, and engage in active collaborations are likely to gain a foothold in this promising market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peptide Antibiotics Market

The Peptide Antibiotics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diseases such as bacterial skin, blood stream, and hospital acquired infections
    • Rising need for peptide antibiotics in hospitals and clinics
    • Improvement in healthcare infrastructure facility
  • Market Restraints
    • Stringent reimbursement policy
  • Market Opportunities
    • Rising product approvals and product launches and R&D initiatives
    • Emerging use in regeneration of skin/bone, prevention of implant-associated infections, cancer therapy and gene delivery
  • Market Challenges
    • Concerns related to instability and toxicity of peptide antibiotics

Porter's Five Forces: A Strategic Tool for Navigating the Peptide Antibiotics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peptide Antibiotics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peptide Antibiotics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peptide Antibiotics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peptide Antibiotics Market

A detailed market share analysis in the Peptide Antibiotics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peptide Antibiotics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peptide Antibiotics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Peptide Antibiotics Market

A strategic analysis of the Peptide Antibiotics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Peptide Antibiotics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly & Company, Eugia US LLC, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Novo Holdings A/S, Pfizer Inc., Sanofi S.A., Savara Inc., Teva Pharmaceutical Industries Ltd., and Theravance Biopharma.

Market Segmentation & Coverage

This research report categorizes the Peptide Antibiotics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-Ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics.
  • Based on Disease, market is studied across Blood Stream Infections, HABP/VABP, and Skin Infections.
  • Based on Route of Administration, market is studied across Injectable, Oral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diseases such as bacterial skin, blood stream, and hospital acquired infections
      • 5.1.1.2. Rising need for peptide antibiotics in hospitals and clinics
      • 5.1.1.3. Improvement in healthcare infrastructure facility
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent reimbursement policy
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising product approvals and product launches and R&D initiatives
      • 5.1.3.2. Emerging use in regeneration of skin/bone, prevention of implant-associated infections, cancer therapy and gene delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to instability and toxicity of peptide antibiotics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Peptide Antibiotics Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Ribosomal Synthesized Peptide Antibiotics
  • 6.3. Ribosomal Synthesized Peptide Antibiotics

7. Peptide Antibiotics Market, by Disease

  • 7.1. Introduction
  • 7.2. Blood Stream Infections
  • 7.3. HABP/VABP
  • 7.4. Skin Infections

8. Peptide Antibiotics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical

9. Peptide Antibiotics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Peptide Antibiotics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Peptide Antibiotics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Peptide Antibiotics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Dr. Reddy's Laboratories Ltd.
  • 4. Eli Lilly & Company
  • 5. Eugia US LLC
  • 6. Fresenius SE & Co. KGaA
  • 7. GlaxoSmithKline PLC
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Novo Holdings A/S
  • 11. Pfizer Inc.
  • 12. Sanofi S.A.
  • 13. Savara Inc.
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Theravance Biopharma

LIST OF FIGURES

  • FIGURE 1. PEPTIDE ANTIBIOTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PEPTIDE ANTIBIOTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PEPTIDE ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PEPTIDE ANTIBIOTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY NON-RIBOSOMAL SYNTHESIZED PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RIBOSOMAL SYNTHESIZED PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY BLOOD STREAM INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HABP/VABP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2023